A multicentre phase II trial to determine the efficacy of vinflunine as second-line therapy in
patients with advanced transitional cell carcinoma (TCC) of the bladder; secondary …

The novel third-generation bifluorinated semisynthetic vinca alkaloid, vinflunine, is a
microtubule inhibitor that shows superior antitumor activity and a favorable safety profile …

There is no standard of care in the UK or Ireland for second-line chemotherapy for patients
with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients …

Introduction: Vinca alkaloid agents have been widely used in several different types of
malignancies. However, cancer cells, ultimately, develop resistance to these agents …

Background Patients with transitional cell carcinoma of the urothelial tract (TCCU) who fail
initial platinum-based chemotherapy for advanced disease represent a challenge in daily …

Aims Vinflunine (VFL) ditartrate, a novel tubulin‐targeted inhibitor, is registered for the
treatment of patients with advanced or metastatic urothelial transitional cell carcinoma. This …

Purpose We comprehensively reviewed current efforts and advances in the field of
chemotherapeutic and biologically targeted treatment options after the failure of cisplatin …

Background To compare long-term, updated overall survival (OS) of patients with advanced
transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine plus best …

With vinflunine there is reasonable hope for a new standard chemotherapy in second-line
management of transitional cell carcinoma. However, due to the reported results with single …

Vinflunine (VFL) is a third-generation bifluorinated semi-synthetic vinca alkaloid obtained by
superacidic chemistry from its parent compound, vinorelbine. As with the other vinca …